In an international phase 3a clinical trial, adolescents with obesity who received once-weekly semaglutide compared to placebo had a 16.1percentt decrease in their body mass index (BMI) while the BMI of those who took placebo rose by 0.6 percent.

from mint - Science https://ift.tt/EZ3coCR
https://ift.tt/h4mPiCb

Post a Comment

Previous Post Next Post